Trial: 202108011

A Phase 1/2 open-label, biomarker-defined cohort trial to evaluate the safety, determine the recommended combination dosing, and assess early antitumor activity of tipifarnib and alpelisib for the treatment of adult participants who have HRAS-overexpressing and/or PIK3CA-mutated and/or -amplified recurrent/metastatic head and neck squamous cell carcinoma (the Kurrent trial)


I/II (Cancer Control)

Principal Investigator

Adkins, Douglas

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: